The demand for radiation pneumonitis treatment is set to increase over the forecast period. This is due to the high incidence of occurrence of symptomatic radiation pneumonitis with incidence rate up to 40% in most patients receiving radiotherapy, as according to the data published by the Journal of European Society for Therapeutic Radiology and Oncology.
These factors extend support to the growth in demand for radiation pneumonitis treatment. Essentially, treatment factors such as chemotherapy and immunotherapy have highest risk associated with radiation pneumonitis. These factors propel the need for radiation pneumonitis treatment.
Get Sample Copy of this Report@ https://www.persistencemarketresearch.com/samples/32641
The advancements in the understanding of molecular mechanisms involving the injury of tissues and the novel methodologies for the prevention and treatment of radiation pneumonitis has led to a drive in demand for radiation pneumonitis treatment.
Additionally, the assessment of treatment factors involving the targeting of cytokine and Growth Factor Expression after radiation will improve the growth of demand in radiation pneumonitis treatment prior to successful clinical models. The adoption of Intensity-modulated Therapy also associates with lower rates of radiation pneumonitis and acts as a supplementary factor for growth in radiation pneumonitis treatment.
There is an extensive amount of research studies involving the incidence of radiation pneumonitis and its management and treatment in Canada. The institutes such as the Canadian Cancer Society offer specialized treatment plans for the management of radiation pneumonitis in addition to offering knowledge and awareness based on procedures involving radiation therapy.
Request for Table of Content@ https://www.persistencemarketresearch.com/toc/32641
The relation between smoking and development of radiation pneumonitis in the region of Europe has impacted the evaluation of radiation pneumonitis treatment for post-radiation therapy.
- Provision Healthcare LLC
- Hitachi Ltd.
- Elekta AB (pub)
- C. R. Bard Inc.
- Optivus Proton Therapy Inc.
- Mevion Medical Systems Inc.
- Panacea Medical Technologies Pvt. Ltd.
- Isoray Medical Inc.
- Varian Medical Systems Inc.
Access Full Report@ https://www.persistencemarketresearch.com/checkout/32641
Key Segments
By Risk of Development
- Patient Related Factors
- Pre-Existing Lung Conditions
- COPD
- Asthma
- Interstitial Lung Disease
- Smoking Associated Hypoxia
- Pre-Existing Lung Conditions
- Treatment Related Factors
- Chemotherapy
- Immunotherapy
- Radiation Therapy
- Surgery
By Technology
- 4D CT ventilation imaging
- Imaging Based Biomarkers: Pre-Treatment FDG
- NTCP Modeling (Risk Assessment)
By End User
- Hospitals
- Research Centers and Laboratories
- Research Institutions
About Us:
Persistence Market Research is here to provide companies a one-stop solution with regards to bettering customer experience. It does engage in gathering appropriate feedback after getting through personalized customer interactions for adding value to customers’ experience by acting as the “missing” link between “customer relationships” and “business outcomes’. The best possible returns are assured therein.
Contact Us:
Persistence Market Research
Address – 305 Broadway, 7th Floor, New York City, NY 10007 United States
U.S. Ph. – +1-646-568-7751
USA-Canada Toll-free – +1 800-961-0353
Sales – sales@persistencemarketresearch.com
Website – https://www.persistencemarketresearch.com